› Forums › Cutaneous Melanoma Community › Dabrafenib/Tramentinib Trial for Stage IIIA/B/C
- This topic has 6 replies, 2 voices, and was last updated 10 years, 5 months ago by Sheepsandcows.
- Post
-
- March 15, 2014 at 2:02 pm
This looks like a good trial for Stage III patients. You may want to ask your doctor about this one!
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD)
This is a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the treatment of melanoma after removal by surgery. Patients with BRAF V600E/K mutation-positive cutaneous melanoma that has been completely removed by surgery but who are at high-risk for recurrence [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] may be eligible. Subjects will be randomized to receive either dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) combination therapy or two placebos for 12 months
- Replies
-
-
-
- May 14, 2014 at 3:07 am
Should someone chose not to participate in the trial, Is there a cancer center in USA where they are using these drugs for dx IIIC and NED after lymph nodes surgery?ba friend was just offered this option and she wants out for the same reason
thank you
-
- May 14, 2014 at 3:07 am
Should someone chose not to participate in the trial, Is there a cancer center in USA where they are using these drugs for dx IIIC and NED after lymph nodes surgery?ba friend was just offered this option and she wants out for the same reason
thank you
-
- May 14, 2014 at 3:07 am
Should someone chose not to participate in the trial, Is there a cancer center in USA where they are using these drugs for dx IIIC and NED after lymph nodes surgery?ba friend was just offered this option and she wants out for the same reason
thank you
-
-
Tagged: cutaneous melanoma
- You must be logged in to reply to this topic.